RIEHEN, Switzerland, September 28, 2022 – Eight early stage startups offering solutions in the life science and digital health sectors have been selected to participate in the third edition of the Israeli-Swiss Lean Launchpad Program. Starting in October, the startups will explore the Israel startup scene in search for business and growth opportunities for their companies.
The hybrid 10-week Swiss-Israel Lean Launchpad programme enables startups to explore the Israeli digital health sector as well as the culture and inner workings of the Israeli startup ecosystem. The programme is tailor-made for the needs of each participating startup. Participants will meet Israeli industry leaders, medical institutions and university representatives as well as entrepreneurs. Group sessions provide first-hand insight into the toolbox of Israeli entrepreneurs, including business model design, pivoting, marketing, storytelling, pitching and more. In addition, the programme includes personal mentoring sessions. The Israeli-Swiss Lean Launchpad Program is organised by the innovation team at the Embassy of Switzerland in Israel and Israeli innovation consultants on behalf of Innosuisse.
Eight startups with an active Innosuisse coaching voucher have been selected to participate in the upcoming edition, which starts with an online session in October 2022. They will attend two in-person parts: a 2-day workshop in November and a week-long visit to Israel in early December 2022.
RIEHEN, Switzerland, April 27, 2022 – Bionter AG, experts in sub-visible particle testing, announced the completion of a $3 million Series Seed financing from Dynamk Capital. Bionter revolutionizes analytical testing of subvisible particles in the biopharmaceutical industry in respect to economy, process time and safety.
Proceeds from this round will help the company to expand their committed team, launch their first solution in 2022 ,and fuel their pipeline with new innovative developments.
“Bionter technology is a game changer in subvisible particle counting, one of the most important quality attributes of administered liquid biologics,” said Reinhard Vogt, chair of the Board of Bionter and Venture Partner at Dynamk Capital”
The financing accelerates the already exceptional momentum for Bionter’s initial offering. Bionter’s complete solution includes a particle counter supported with single-use consumables, maintenance and training, applicable for biotech’s drug product sector and based on a new combination light obscuration technology and smart automation.
A challenge faced by the biopharmaceutical industry is how to minimize the amount of costly sample required to determine particle count. Bionter’s device reduces the overall sample volume required, saving material for other analytical endpoints, hence reducing costs. Its smart automated workflow drives efficiency, minimizes human interaction and therefore improving reliability, data integrity and in turn patient safety. Bionter’s particle counter is also compliant to current USP/EP/JP regulations familiar with manufacturers.
The company has completed development of its patented technology and will launch it end of May 2022.
“This financing enables us to bring our first product to our customers while driving the development of new innovations,” said Dr. Tobias Werk, CEO of Bionter. “We are thrilled to have Dynamk Capital join our team, as they provide a wealth of experience growing life science tools companies and help position Bionter and help us to make our vision a reality.”
About Bionter AG
Bionter (www.bionter.com) is a recently founded Switzerland based company with the purpose of revolutionizing analytical testing for the benefit of people’s health. Bionter is driving patient safety, cost efficiency and sustainability through disruptive innovations in particle testing that are increasing the quality of drug product testing. Bionter`s first product is a particle counter that is not only fully automated but also allows non-destructive sample testing.
About Dynamk Capital
Dynamk Capital is a growth equity and venture capital firm focused on life sciences industrials. Dynamk’s investment strategy is centered on identifying companies developing disruptive technologies, tools, and services that enable the full biopharma continuum across discovery, development, and manufacturing of biotherapeutics, including cell & gene therapies and vaccines. Please visit www.dynamk.vc for more information.
RIEHEN, Switzerland, March 22, 2022 – A Swiss start-up is hoping to lower the costs of biologics development by adapting a quality control technology to the pharmaceutical industry. The new light obscuration instrument for sub-visible particle testing during product formulation is Bionter’s first product and will be launched between May and August.
“The light obscuration instrument is the first in a family of products, and the unique thing is that it doesn’t consume samples during testing,” explains Bionter’s CEO, Tobias Werk, PhD. “During formulation development, light obscuration alone consumes thousands and thousands of samples, and the material alone easily exceeds $1,000 for a single sample. So, by making it non-destructive, you open lots of opportunities to get insights faster and lower the cost of development.”
According to Werk, light obscuration technology is an established technique for sub-visible particle testing in the formulation phase of biologics development. However, because the technology was adapted from aerospace, he says it really wasn’t configured to the specific needs of the pharmaceutical industry.
“Light obscuration technology was developed around 1960 and was adopted into pharmaceutical [research] as a requirement because it could substitute for microscopy,” he explains. But, Werk says, since the technology has largely remained unchanged, except for the substitution of a laser for bulbs in the 1980s, this inspired him to set up Bionter in 2020 with the aim of creating tailored technologies for the pharma industry.
The new light obscuration instrument avoids destroying the sample by incorporating a drying step into the analytical process, he points out, which prevents contamination dilution as different samples are moved through the system.
Werk automated the instrument to allow operators to leave the equipment and changed the fluidics to deal with the viscosities for high-concentrated protein formulations and other biologics.
The new instrument, he notes, also didn’t require specific regulatory approval. “Our method uses off-the-shelf light obscuration technology, so it still conforms with regulations,” he says.
Werk is scheduled to speak about his technology this week at the Bioprocessing Summit Europe.
08/02/2023 – 22/02/2023